Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Single- and Double-dose Icodextrin in PD Patients
NCT06552546Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Polymer-based Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Open-label trial of icodextrin in end stage renal disease (ESRD) (2 arms), sponsored by Peking University First Hospital. Primary endpoints: Peak Concentration at Day 14, Time to Peak Concentration at Day 14 and 3 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
icodextrin
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT06552546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06552546.